SynthesisFrontiers in medicine2022
Diagnostic Utility of Non-invasive Tests for Inflammatory Bowel Disease: An Umbrella Review.
Synthesis in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Review Article: Extending the Frontiers of Intestinal Ultrasound Knowledge, Performance and Expansion.Alimentary pharmacology & therapeutics · 2026Pooled it
- Salivary Biomarkers in Crohn's Disease and Ulcerative Colitis: A Scoping Review and Evidence Map.International journal of molecular sciences · 2025Article
- Escherichia coli gene expression is influenced more by gut environmental changes from inflammation and microbiota modulation than by colitis severity.Scientific reports · 2025Article
- Tissue MicroRNA Expression Signatures as Diagnostic Biomarkers and Predictors of Residual Disease Activity and Relapse in Treatment-Naïve Pediatric Inflammatory Bowel Disease.Inflammatory bowel diseases · 2025Article
- From Cytokines to Biomarkers: Mapping the Immunopathology of Inflammatory Bowel Disease.Cells · 2025Review
- Probiotic acoustic biosensors for noninvasive imaging of gut inflammation.Nature communications · 2025Article
- Galectin-3-Insights from Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.International journal of molecular sciences · 2025Review
- Serum Neutrophil Biomarkers to Predict Crohn's Disease Progression and Infliximab Treatment Outcomes.United European gastroenterology journal · 2025Observational
- Sex-specific associations between systemic autoantibodies and allergic sensitization or allergic disease - results from a population-based study.Frontiers in immunology · 2025Article
- Precision Medicine in Inflammatory Bowel Disease: A Spotlight on Emerging Molecular Biomarkers.Biomedicines · 2024Review
- Diagnostic Guidance for C. difficile Infections.Advances in experimental medicine and biology · 2024Article
- Altered fecal bile acid composition in active ulcerative colitis.Lipids in health and disease · 2023Article
- Fecal short chain fatty acids and urinary 3-indoxyl sulfate do not discriminate between patients with Crohn´s disease and ulcerative colitis and are not of diagnostic utility for predicting disease severity.Lipids in health and disease · 2023Article
- Biomarkers in IBD: What to Utilize for the Diagnosis?Diagnostics (Basel, Switzerland) · 2023Review
- Review
- Unmet Challenges in Patients with Crohn's Disease.Journal of clinical medicine · 2023Review
- Fecal and Urinary Adipokines as Disease Biomarkers.Biomedicines · 2023Review
- Advancing the precision management of inflammatory bowel disease in the era of omics approaches and new technology.World journal of gastroenterology · 2023Review
- Predicting pediatric Crohn's disease based on six mRNA-constructed risk signature using comprehensive bioinformatic approaches.Open life sciences · 2023Article
- Serum cytokines MCP-1 and GCS-F as potential biomarkers in pediatric inflammatory bowel disease.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to consolidate evidence from published systematic reviews and meta-analyses evaluating the diagnostic performances of non-invasive tests for inflammatory bowel disease (IBD) in various clinical conditions and age groups. Methods: Two independent reviewers systematically identified and appraised systematic reviews and meta-analyses assessing the diagnostic utility of non-invasive tests for IBD. Each association was categorized as adults, children, and mixed population, based on the age ranges of patients included in the primary studies. We classified clinical scenarios into diagnosis, activity assessment, and predicting recurrence. Results: In total, 106 assessments from 43 reviews were included, with 17 non-invasive tests. Fecal calprotectin (FC) and fecal lactoferrin (FL) were the most sensitive for distinguishing IBD from non-IBD. However, anti-neutrophil cytoplasmic antibodies (ANCA) and FL were the most specific for it. FC and FL were the most sensitive and specific tests, respectively, to distinguish IBD from irritable bowel syndrome (IBS). Anti- Conclusion: In this umbrella review, we summarized the diagnostic performance of non-invasive tests for IBD in various clinical conditions and age groups. Clinicians can use the suggested non-invasive test depending on the appropriate clinical situation in IBD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.